Total Payments
$1.4M
2024 Payments
$87,045
Companies
12
Transactions
180
Payment Breakdown by Category
Consulting$682,430 (50.4%)
Research$671,175 (49.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $682,430 | 105 | 50.4% |
| Unspecified | $671,175 | 75 | 49.6% |
Payments by Type
General
$682,430
105 transactions
Research
$671,175
75 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Acerta Pharma LLC | $657,590 | 54 | $0 (2022) |
| Janssen Research & Development, LLC | $188,490 | 18 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $177,175 | 10 | $0 (2021) |
| ABBVIE INC. | $100,300 | 26 | $0 (2024) |
| AstraZeneca UK Limited | $99,715 | 20 | $0 (2024) |
| Hoffmann-La Roche Limited | $71,930 | 5 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $27,095 | 26 | $0 (2020) |
| BeiGene, Ltd. | $17,840 | 7 | $0 (2024) |
| BeiGene (Suzhou) Co., Ltd. | $8,445 | 3 | $0 (2021) |
| Verastem, Inc. | $2,775 | 8 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87,045 | 21 | AstraZeneca UK Limited ($40,040) |
| 2023 | $43,945 | 9 | AstraZeneca UK Limited ($43,945) |
| 2022 | $59,250 | 19 | Acerta Pharma LLC ($46,200) |
| 2021 | $315,250 | 36 | Acerta Pharma LLC ($178,105) |
| 2020 | $326,655 | 36 | Acerta Pharma LLC ($234,410) |
| 2019 | $220,370 | 21 | Acerta Pharma LLC ($146,345) |
| 2018 | $179,345 | 12 | E.R. Squibb & Sons, L.L.C. ($89,850) |
| 2017 | $121,745 | 26 | Hoffmann-La Roche Limited ($71,930) |
All Payment Transactions
180 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $8,690.00 | General |
| Category: Oncology | ||||||
| 12/17/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $1,380.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $3,205.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $770.00 | General |
| Category: Oncology | ||||||
| 10/15/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 09/10/2024 | BeiGene, Ltd. | — | Consulting Fee | Cash or cash equivalent | $9,060.00 | General |
| 09/10/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,210.00 | General |
| Category: Oncology | ||||||
| 08/27/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $1,925.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $2,045.00 | General |
| Category: Oncology | ||||||
| 08/20/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 08/13/2024 | BeiGene, Ltd. | BRUKINSA (Drug) | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 07/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,285.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 06/18/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $110.00 | General |
| Category: Oncology | ||||||
| 05/21/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $220.00 | General |
| Category: Oncology | ||||||
| 05/14/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $2,160.00 | Research |
| Study: A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 04/23/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $4,950.00 | General |
| Category: Oncology | ||||||
| 04/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $3,780.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 03/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $23,415.00 | Research |
| Study: A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma • Category: ONCOLOGY | ||||||
| 03/12/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $11,605.00 | General |
| Category: Oncology | ||||||
| 02/20/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $10,065.00 | General |
| Category: Oncology | ||||||
| 01/23/2024 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $495.00 | General |
| Category: Oncology | ||||||
| 12/12/2023 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $6,545.00 | General |
| Category: Oncology | ||||||
| 11/28/2023 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $19,745.00 | General |
| Category: Oncology | ||||||
| 10/17/2023 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $2,310.00 | General |
| Category: Oncology | ||||||
| 09/26/2023 | AstraZeneca UK Limited | CALQUENCE (Drug) | Consulting Fee | Cash or cash equivalent | $3,080.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia | Acerta Pharma LLC | $118,210 | 1 |
| A Randomized Open label Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the Firstline Treatment of Subjects with Chronic Lymphocytic Leukemia CLL Small Lymphocytic Lymphoma SLL | Janssen Research & Development, LLC | $104,045 | 7 |
| Non Comparative Multi Cohort Single Arm Open Label Phase 2 Study of Nivolumab BMS 936558 | E.R. Squibb & Sons, L.L.C. | $85,200 | 1 |
| A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Janssen Research & Development, LLC | $84,445 | 11 |
| PHASE 3 R R CLL WITH GDC0199 BR | Hoffmann-La Roche Limited | $71,930 | 5 |
| Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab BMS-936558 in Classical Hodgkin Lymphoma cHL Subjects | E.R. Squibb & Sons, L.L.C. | $60,975 | 2 |
| M14-032 | AbbVie, Inc. | $29,450 | 6 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma | ABBVIE INC. | $28,605 | 4 |
| M13-365 | AbbVie, Inc. | $20,010 | 3 |
| Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects | E.R. Squibb & Sons, L.L.C. | $13,025 | 3 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemiax2FSmall Lymphocytic Lymphoma | ABBVIE INC. | $11,050 | 7 |
| Non Comparative Multi Cohort Single Arm Open Label Phase 2 Study of Nivolumab BMS 936558 in Classical Hodgkin Lymphoma cHL Subjects | E.R. Squibb & Sons, L.L.C. | $9,975 | 3 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | BeiGene (Suzhou) Co., Ltd. | $8,445 | 3 |
| A Single Arm Open Label Phase 2 Study of Nivolumab BMS 936558 in Subjects With Relapsed or Refractory Follicular Lymphoma FL | E.R. Squibb & Sons, L.L.C. | $8,000 | 1 |
| M12-175 | AbbVie, Inc. | $4,900 | 1 |
| M14-728 | AbbVie, Inc. | $3,725 | 3 |
| A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ABBVIE INC. | $2,160 | 1 |
| Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma | Pharmacyclics LLC, An AbbVie Company | $2,100 | 2 |
| A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | BeiGene, Ltd. | $1,600 | 1 |
| A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO) | Verastem, Inc. | $1,425 | 4 |
| IPI-145-06 | Verastem, Inc. | $1,350 | 4 |
| A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | ABBVIE INC. | $400.00 | 1 |
| IPI-145-06 | Secura Bio, Inc. | $150.00 | 1 |
About Dr. Stephanie Bernstein, MD
Dr. Stephanie Bernstein, MD is a Hematology & Oncology healthcare provider based in Winchester, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1396814265.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephanie Bernstein, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $87,045 received in 2024. These payments were reported across 180 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($682,430).
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Winchester, MA
- Active Since 11/07/2006
- Last Updated 10/21/2009
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1396814265
Products in Payments
- CALQUENCE (Drug) $757,305
- OPDIVO (Biological) $177,175
- VENCLEXTA (Biological) $71,930
- Venclexta (Drug) $58,085
- VENCLEXTA (Drug) $42,215
- KEYTRUDA (Biological) $27,095
- BRUKINSA (Drug) $15,625
- Copiktra (Drug) $2,925
- IMBRUVICA (Drug) $2,100
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Winchester
Dr. William Houck, M.d, M.D
Hematology & Oncology — Payments: $12,534
Hematology & Oncology $12,534
Dr. Richard Ingram, M.d, M.D
Hematology & Oncology — Payments: $1,839
Hematology & Oncology $1,839
Dr. Michael Mccusker, M.d, M.D
Hematology & Oncology — Payments: $1,166
Hematology & Oncology $1,166
Lindsey Morgan O'brien, Md, MD
Hematology & Oncology — Payments: $1,143
Hematology & Oncology $1,143
Dr. Matthew Jones, Md, MD
Hematology & Oncology — Payments: $910.73
Hematology & Oncology $910.73
Dr. Nicholas Gemma, M.d, M.D
Hematology & Oncology — Payments: $770.70
Hematology & Oncology $770.70